General information
Heidelberg Pharma AG
Gregor-Mendel-Straße 22
68526 Ladenburg, Baden-Württemberg
Germany
Contact person: Jan Schmidt-Brand, Chief Executive Officer
Company main phone: +49 (6203) 10090
Company main fax: +49 (6203) 100919
Website: https://www.heidelberg-pharma.com
Year founded: | 1997
|
Source of foundation: | Independent foundation |
No. of employees: |
Worldwide: 98 |
No. of R&D employees: |
Worldwide: 62 |
Corporate description / mission:
Heidelberg Pharma AG is a biopharmaceutical company working in the field of oncology. The company is focused on the development of Antibody Drug Conjugates (ADCs) for the treatment of oncological diseases. Heidelberg Pharma's so-called ATACs are ADCs based on the ATAC technology that uses Amanitin as an active ingredient. The biological mechanism of action of the Amanitin toxin represents a new therapeutic principle. The proprietary lead candidate HDP-101 is a BCMA-ATAC for multiple myeloma. Further preclinical development candidates are HDP-102, a CD37 ATAC for Non-Hodgkin lymphoma and HDP-103, a PSMA ATAC for metastatic castration-resistant prostate cancer.
State of ownership: Publicly listed on stock exchange
Headquarters: HQ: Yes
IPO (year): 2006
Categorization
Sector: |
- Biotechnology - Therapeutics and Diagnostics
|
Subsector: |
- Anti-infectives
- Antibody-drug-conjugate
- Small molecules
|
Primary therapeutic areas: |
- Infectious and parasitic diseases / infectiology / parasitology
- Neoplasms / cancer / oncology
|
Customer segments: |
- Large biotech & big pharma
- Small biotech
|
Summary Products / Services / Technologies
Number of Biotech Products
Pre-clinical: | 7 | |
Phase I: | 3 | |
Phase II: | 3 | |
Phase III: | 1 | |
Description of products:
HDP-101 - BCMA ATAC
HDP-102 - CD37 ATAC
HDP-103 - PSMA ATAC
HDP-104 - GCC ATAC
Technology used:
ADC technology
ATAC technology
Financing details
Market cap. / valuation: | USD 119.69M | |
Collaborations & Clients
Partnering strategy / collaborations:
e.g. Takeda Pharmaceutical Company Limited, Chiome Bioscience, Binghamton University (State University of New York)